Lumos Faces Commercial Challenges Despite FebriDx® CLIA Waiver Expansion
Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.
- US FDA grants CLIA waiver and 510(k) clearance for FebriDx®
- Milestone payments of US$5.5 million triggered from Phase Scientific and BARDA
- Addressable US market expands to 80 million patients annually
- Market opportunity grows 15-fold to over US$1 billion
- FebriDx® now deployable in 300,000+ US healthcare locations
A Regulatory Breakthrough
In a significant regulatory and commercial milestone, Lumos Diagnostics (ASX:LDX) has announced that the US Food and Drug Administration (FDA) has granted a Clinical Laboratory Improvement Amendments (CLIA) waiver for its flagship point-of-care test, FebriDx®. This follows the earlier 510(k) clearance and marks a transformative moment for the company’s US market strategy.
The CLIA waiver allows FebriDx® to be used in a broader range of healthcare settings beyond traditional hospital laboratories, including primary care physician offices, urgent care clinics, retail health and pharmacy clinics, and community health centres. This expansion opens access to over 300,000 locations across the United States, vastly increasing the test’s availability.
Market Expansion and Financial Impact
Prior to this approval, FebriDx® was limited to moderate complexity clinical environments, restricting its reach primarily to hospitals and laboratories. The new waiver expands the addressable market to approximately 80 million patients annually who present with acute respiratory infections, unlocking a market opportunity exceeding US$1 billion. This represents a 15-fold increase compared to the market potential before the waiver.
Alongside this regulatory success, Lumos has triggered milestone payments totalling US$5.5 million. Phase Scientific, Lumos’ exclusive US distributor, will pay US$5 million immediately, while the Biomedical Advanced Research and Development Authority (BARDA) will contribute approximately US$0.5 million. These funds will strengthen Lumos’ balance sheet and support the broader commercial rollout of FebriDx® in the US.
Strategic Partnerships and Future Prospects
Lumos’ US commercial strategy is underpinned by partnerships with Phase Scientific, PRO-spectus, and AcuityMD, focusing on healthcare provider education, workflow integration, and securing reimbursement from private payors. CEO Doug Ward emphasised the milestone’s significance, highlighting how the CLIA waiver enables rapid, accurate diagnosis at the point of care, improving patient outcomes and antibiotic stewardship.
Looking ahead, Lumos is pursuing a pediatric study to extend FebriDx® use to children aged 2 to 12 years. Success in this initiative could further broaden patient access and support more informed antibiotic prescribing across a wider demographic.
Public-Private Collaboration
The project received federal funding support from the US Department of Health and Human Services and BARDA, underscoring the importance of public-private partnerships in addressing antimicrobial resistance and enhancing healthcare delivery. This collaboration highlights the strategic value of FebriDx® in managing acute respiratory infections more effectively in outpatient settings.
Bottom Line?
With FDA CLIA waiver in hand, Lumos is poised to reshape respiratory infection diagnostics across the US outpatient landscape.
Questions in the middle?
- How quickly will FebriDx® adoption scale across the newly accessible 300,000+ US locations?
- What reimbursement pathways will Lumos secure to support widespread commercial uptake?
- Will the pediatric study succeed in expanding FebriDx® use to younger patients, and when?
